© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
June 27, 2022
Lenvima (lenvatinib) is approved for the treatment of thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma.
June 21, 2022
Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 to lower blood glucose levels.